Dianthus Therapeutics Inc. (DNTH)
Who owns Dianthus Therapeutics Inc. (DNTH)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.9% of the shares are freely tradable; institutional investors hold 120.4%.
Ownership Structure
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 14.21 | 7,767,686 | +20.8 | 03/31/2026 |
| Avidity Partners Management LP | 7.70 | 4,208,368 | +100.0 | 03/31/2026 |
| BlackRock Inc | 5.81 | 3,175,703 | +65.8 | 03/31/2026 |
| RA Capital Management, LLC | 4.78 | 2,611,733 | +62.0 | 03/31/2026 |
| Wellington Management Company LLP | 4.75 | 2,595,783 | +3.7 | 03/31/2026 |
| Fairmount Funds Management LLC | 4.64 | 2,537,191 | +18.7 | 03/31/2026 |
| Vanguard Group Inc | 3.75 | 2,048,452 | +24.7 | 12/31/2025 |
| Vanguard Capital Management, LLC | 3.72 | 2,031,249 | +0.0 | 03/31/2026 |
| Octagon Capital Advisors LP | 3.56 | 1,946,667 | -19.4 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Fidelity Growth Compy Commingled Pl S | 3.87 | 2,112,872 | +0.3 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 9. Jul 2026 | Savitz Ryan | EVP, CFO & CBO | Sell | 5,566 | 101.97 | 567,565 |
| 9. Jul 2026 | Savitz Ryan | EVP, CFO & CBO | Sell | 15,329 | 101.24 | 1,551,908 |
| 9. Jul 2026 | Savitz Ryan | EVP, CFO & CBO | Sell | 10,354 | 100.22 | 1,037,678 |
| 9. Jul 2026 | Savitz Ryan | EVP, CFO & CBO | Other | 31,249 | 21.77 | 680,291 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.